Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Growth in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 120,900 shares, a growth of 19.2% from the November 15th total of 101,400 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily trading volume, of 143,400 shares, the days-to-cover ratio is presently 0.8 days.

Bolt Biotherapeutics Stock Down 0.1 %

Bolt Biotherapeutics stock opened at $0.53 on Monday. Bolt Biotherapeutics has a twelve month low of $0.51 and a twelve month high of $1.56. The stock has a 50 day moving average of $0.62 and a two-hundred day moving average of $0.67. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $20.20 million, a price-to-earnings ratio of -0.31 and a beta of 0.93.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million. As a group, research analysts expect that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

Institutional Trading of Bolt Biotherapeutics

Several hedge funds have recently modified their holdings of BOLT. Assenagon Asset Management S.A. acquired a new stake in shares of Bolt Biotherapeutics in the 2nd quarter valued at approximately $26,000. FMR LLC lifted its holdings in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares during the period. Finally, Acuitas Investments LLC lifted its holdings in shares of Bolt Biotherapeutics by 21.7% in the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after buying an additional 112,555 shares during the period. 86.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.50.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.